TY - JOUR
T1 - Management of Locally Advanced Pancreatic Cancer
T2 - Results of an International Survey of Current Practice
AU - Reames, Bradley N.
AU - Blair, Alex B.
AU - Krell, Robert W.
AU - Groot, Vincent P.
AU - Gemenetzis, Georgios
AU - Padussis, James C.
AU - Thayer, Sarah P.
AU - Falconi, Massimo
AU - Wolfgang, Christopher L.
AU - Weiss, Matthew J.
AU - Are, Chandrakanth
AU - He, Jin
N1 - Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Objective:The aim of this study was to investigate surgeon preferences for the management of patients with locally advanced pancreatic cancer (LAPC).Background:Select patients with LAPC may become candidates for curative resection following neoadjuvant therapy, and recent reports of survival are encouraging. Yet the optimal management approach remains unclear.Methods:An extensive electronic survey was systematically distributed by email to an international cohort of pancreas surgeons. Data collected included practice characteristics, management preferences, attitudes regarding contraindications to surgery, and 6 clinical vignettes of patients that ultimately received a margin negative resection (with detailed videos of post-neoadjuvant imaging) to assess propensity for surgical exploration if resection status is not known.Results:A total of 153 eligible responses were received from 4 continents. Median duration of practice is 12 years (interquartile range 6-20) and 77% work in a university setting. Most surgeons (86%) are considered high volume (>10 resections/yr), 33% offer a minimally-invasive approach, and 50% offer arterial resections in select patients. Most (72%) always recommend neoadjuvant chemotherapy, and 65% prefer FOLFIRINOX. Preferences for the duration of chemotherapy varied widely: 39% prefer ≥2 months, 43% prefer ≥4 months, and 11% prefer ≥6 months. Forty-one percent frequently recommend neoadjuvant radiotherapy, and 53% prefer 5 to 6 weeks of chemoradiation. The proportion of surgeons favoring exploration following neoadjuvant varied extensively across 5 vignettes of LAPC, from 14% to 53%. In a vignette of oligometastatic liver metastases, 31% would offer exploration if a favorable therapy response is observed.Conclusions:In an international cohort of pancreas surgeons, there is substantial variation in management preferences, perceived contraindications to surgery, and the propensity to consider exploration in LAPC. These results emphasize the importance of a robust and nuanced multidisciplinary discussion for each patient, and suggest an evolving concept of "resectability.".
AB - Objective:The aim of this study was to investigate surgeon preferences for the management of patients with locally advanced pancreatic cancer (LAPC).Background:Select patients with LAPC may become candidates for curative resection following neoadjuvant therapy, and recent reports of survival are encouraging. Yet the optimal management approach remains unclear.Methods:An extensive electronic survey was systematically distributed by email to an international cohort of pancreas surgeons. Data collected included practice characteristics, management preferences, attitudes regarding contraindications to surgery, and 6 clinical vignettes of patients that ultimately received a margin negative resection (with detailed videos of post-neoadjuvant imaging) to assess propensity for surgical exploration if resection status is not known.Results:A total of 153 eligible responses were received from 4 continents. Median duration of practice is 12 years (interquartile range 6-20) and 77% work in a university setting. Most surgeons (86%) are considered high volume (>10 resections/yr), 33% offer a minimally-invasive approach, and 50% offer arterial resections in select patients. Most (72%) always recommend neoadjuvant chemotherapy, and 65% prefer FOLFIRINOX. Preferences for the duration of chemotherapy varied widely: 39% prefer ≥2 months, 43% prefer ≥4 months, and 11% prefer ≥6 months. Forty-one percent frequently recommend neoadjuvant radiotherapy, and 53% prefer 5 to 6 weeks of chemoradiation. The proportion of surgeons favoring exploration following neoadjuvant varied extensively across 5 vignettes of LAPC, from 14% to 53%. In a vignette of oligometastatic liver metastases, 31% would offer exploration if a favorable therapy response is observed.Conclusions:In an international cohort of pancreas surgeons, there is substantial variation in management preferences, perceived contraindications to surgery, and the propensity to consider exploration in LAPC. These results emphasize the importance of a robust and nuanced multidisciplinary discussion for each patient, and suggest an evolving concept of "resectability.".
KW - locally advanced pancreas cancer
KW - multidisciplinary management
KW - pancreas cancer
KW - pancreas surgery
KW - survey research
UR - http://www.scopus.com/inward/record.url?scp=85071194074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071194074&partnerID=8YFLogxK
U2 - 10.1097/SLA.0000000000003568
DO - 10.1097/SLA.0000000000003568
M3 - Article
C2 - 31449138
AN - SCOPUS:85071194074
SN - 0003-4932
VL - 273
SP - 1173
EP - 1181
JO - Annals of surgery
JF - Annals of surgery
IS - 6
ER -